leisure time -WSS

leisure time

author：knowledge 2025-09-27 12:49:19 - browse：12

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 4th of July breaks record for highest global temperature ever measured

focus

WSS

Meta looks to target Twitter with a rival app called Threads

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Listen: Biogen's messy board & Laronde's data problem

State of the Union pitch: Bigger Medicare drug price negotiations

Readout Newsletter: BridgeBio, Akero, and human embryo models

7 people shot in DC, police say

focus

leisure time

focus

United colonoscopy coverage change 'may cost lives,' doctors say

PhRMA sues HHS over Medicare drug price negotiation

After affirmative action ruling, medical educators look to 'holistic review'

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden's 'march

New air purifier tech could be key to improving indoor air quality

$1 billion proposal to grow Boston, Massachusetts biotech

Trump demands the U.S. pay no more for drugs than other countries … again

Biden's 'march

entertainment

Pfizer's Covid pill remains 89% effective in final analysis, company says

Readout Newsletter: BridgeBio, Akero, and human embryo models

State of the Union pitch: Bigger Medicare drug price negotiations

Ozempic has benefits for kidney disease as well as diabetes

4th of July breaks record for highest global temperature ever measured

IVF doctors demand details after CooperSurgical lawsuit

focus

explore

focus

focus